Dendrimers: Analytical characterization and applications

Biricova, V.; Lázníčková, Alice

doi:10.1016/j.bioorg.2009.07.006

Cited by 97 publications

(34 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HDMBr is also known to neutralize highly negatively charged anticoagulation agent, heparin (39). The PAMAM dendrimer is a macromolecular platform for carrying drug, gene, siRNA and imaging agents in vivo (40). Depending on their surface chemistry PAMAM dendrimers can also act as active therapeutic agents.…”

Section: Discussionmentioning

confidence: 99%

Nucleic acid-binding polymers as anti-inflammatory agents

Lee

Sohn²,

Zhang

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

129

125

View full text Add to dashboard Cite

Dead and dying cells release nucleic acids. These extracellular RNAs and DNAs can be taken up by inflammatory cells and activate multiple nucleic acid-sensing toll-like receptors (TLR3, 7, 8, and 9). The inappropriate activation of these TLRs can engender a variety of inflammatory and autoimmune diseases. The redundancy of the TLR family encouraged us to seek materials that can neutralize the proinflammatory effects of any nucleic acid regardless of its sequence, structure or chemistry. Herein we demonstrate that certain nucleic acid-binding polymers can inhibit activation of all nucleic acid-sensing TLRs irrespective of whether they recognize ssRNA, dsRNA or hypomethylated DNA. Furthermore, systemic administration of such polymers can prevent fatal liver injury engendered by proinflammatory nucleic acids in an acute toxic shock model in mice. Therefore these polymers represent a novel class of anti-inflammatory agent that can act as molecular scavengers to neutralize the proinflammatory effects of various nucleic acids.

show abstract

Section: Discussionmentioning

confidence: 99%

Nucleic acid-binding polymers as anti-inflammatory agents

Lee

Sohn²,

Zhang

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

129

125

View full text Add to dashboard Cite

show abstract

“…[8][9][10][11][12] These applications include drug delivery, gene delivery, enzyme and protein immobilization, magnetic resonance imaging (MRI), dendrimer-protein conjugates, dendrimer-peptide conjugates, etc. 5,6,8,11,[13][14][15] These unique nonlinear polymers have many functional end groups that can be converted to other groups by functional group inversion (FGI) method.…”

Section: -7mentioning

confidence: 99%

Covalent Immobilization of Trypsin on a Novel Aldehyde-Terminated PAMAM Dendrimer

Hamidi¹,

Rashidi²,

Asgari³

et al. 2012

Bulletin of the Korean Chemical Society

View full text Add to dashboard Cite

Dendrimers are a novel class of nonlinear polymers and due to their extensive applications in different fields, called versatile polymers. Polyamidoamine (PAMAM) dendrimers are one of the most important dendrimers that have many applications in nanobiotechnology and industry. Generally aldehyde terminated dendrimers are prepared by activation of amine terminated dendrimers by glutaraldehyde which has two problems, toxicity and possibility of crosslink formation. In this study, novel aldehyde-terminated PAMAM dendrimer was prepared and used for covalent immobilization of trypsin by the aim of finding a special reagent which can prevent crosslinking and deactivation of the enzyme. For this purpose aminoacetaldehydedimethylacetal (AADA) was used as spacer group between aldehyde-terminated PAMAM and trypsin.The findings of this study showed that immobilization of trypsin not only resulted higher optimal temperature, but also increased the thermal stability of the immobilized enzyme in comparison to the free enzyme.

show abstract

“…Dendrimers are tree-like, nanostructured polymers that have received significant attention as drug delivery systems, because of their well-defined size, tailored structure and potentially favourable biodistribution (Biricova and Laznickova, 2009). Dendrimer-based drug delivery systems can be manufactured to provide theoretically almost any size, but are commonly 10-20 nm in diameter and show promise as agents for imaging (Kobayashi and Brechbiel, 2004), gene therapy (Dufes et al, 2005), drug delivery (Svenson, 2009) and biological adhesive (Joshi and Grinstaff, 2008).…”

Section: Dendrimersmentioning

confidence: 99%

Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling

Moss

Siccardi

2014

British J Pharmacology

View full text Add to dashboard Cite

The delivery of therapeutic agents is characterized by numerous challenges including poor absorption, low penetration in target tissues and non-specific dissemination in organs, leading to toxicity or poor drug exposure. Several nanomedicine strategies have emerged as an advanced approach to enhance drug delivery and improve the treatment of several diseases. Numerous processes mediate the pharmacokinetics of nanoformulations, with the absorption, distribution, metabolism and elimination (ADME) being poorly understood and often differing substantially from traditional formulations. Understanding how nanoformulation composition and physicochemical properties influence drug distribution in the human body is of central importance when developing future treatment strategies. A helpful pharmacological tool to simulate the distribution of nanoformulations is represented by physiologically based pharmacokinetics (PBPK) modelling, which integrates system data describing a population of interest with drug/nanoparticle in vitro data through a mathematical description of ADME. The application of PBPK models for nanomedicine is in its infancy and characterized by several challenges. The integration of property-distribution relationships in PBPK models may benefit nanomedicine research, giving opportunities for innovative development of nanotechnologies. PBPK modelling has the potential to improve our understanding of the mechanisms underpinning nanoformulation disposition and allow for more rapid and accurate determination of their kinetics. This review provides an overview of the current knowledge of nanomedicine distribution and the use of PBPK modelling in the characterization of nanoformulations with optimal pharmacokinetics. LINKED ARTICLESThis article is part of a themed section on Nanomedicine. To view the other articles in this section visit http://dx

show abstract

Dendrimers: Analytical characterization and applications

Cited by 97 publications

References 72 publications

Nucleic acid-binding polymers as anti-inflammatory agents

Nucleic acid-binding polymers as anti-inflammatory agents

Covalent Immobilization of Trypsin on a Novel Aldehyde-Terminated PAMAM Dendrimer

Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling

Contact Info

Product

Resources

About